Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statements of Operations and Comprehensive Loss

v3.24.1.1.u2
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Mar. 31, 2024
Mar. 31, 2023
Operating expenses:        
Research and development $ 12,401 $ 14,231 $ 36,654 $ 32,880
General and administrative 3,812 2,911 10,667 8,872
Total operating expenses 16,213 17,142 47,321 41,752
Operating loss (16,213) (17,142) (47,321) (41,752)
Non-operating income (expense):        
Interest and other income, net 1,122 1,484 3,829 2,733
Loss from change in fair value of derivative liabilities (1,959) (14) (1,991) (40)
Total non-operating income (expense), net (837) 1,470 1,838 2,693
Net loss (17,050) (15,672) (45,483) (39,059)
Other comprehensive income (loss):        
Net unrealized gain (loss) on available-for-sale marketable debt securities (30) (132) 273 (132)
Comprehensive loss $ (17,080) $ (15,804) $ (45,210) $ (39,191)
Net loss per common share - basic (in dollars per share) $ (0.34) $ (0.30) $ (0.89) $ (0.76)
Net loss per common share - diluted (in dollars per share) $ (0.34) $ (0.30) $ (0.89) $ (0.76)
Weighted average number of common shares outstanding - basic (in shares) 50,811 51,409 51,212 51,113
Weighted average number of common shares outstanding - diluted (in shares) 50,811 51,409 51,212 51,113